AEON vs. CKPT, CALC, KZR, EGRX, ANVS, IMMX, RPHM, CELU, ALRN, and EQ
Should you be buying AEON Biopharma stock or one of its competitors? The main competitors of AEON Biopharma include Checkpoint Therapeutics (CKPT), CalciMedica (CALC), Kezar Life Sciences (KZR), Eagle Pharmaceuticals (EGRX), Annovis Bio (ANVS), Immix Biopharma (IMMX), Reneo Pharmaceuticals (RPHM), Celularity (CELU), Aileron Therapeutics (ALRN), and Equillium (EQ). These companies are all part of the "pharmaceutical preparations" industry.
Checkpoint Therapeutics (NASDAQ:CKPT) and AEON Biopharma (NASDAQ:AEON) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment, institutional ownership and community ranking.
22.0% of Checkpoint Therapeutics shares are held by institutional investors. Comparatively, 22.8% of AEON Biopharma shares are held by institutional investors. 2.1% of Checkpoint Therapeutics shares are held by insiders. Comparatively, 20.0% of AEON Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Checkpoint Therapeutics received 166 more outperform votes than AEON Biopharma when rated by MarketBeat users. However, 100.00% of users gave AEON Biopharma an outperform vote while only 66.15% of users gave Checkpoint Therapeutics an outperform vote.
Checkpoint Therapeutics has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.Comparatively, AEON Biopharma has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500.
In the previous week, Checkpoint Therapeutics had 9 more articles in the media than AEON Biopharma. MarketBeat recorded 15 mentions for Checkpoint Therapeutics and 6 mentions for AEON Biopharma. AEON Biopharma's average media sentiment score of 0.43 beat Checkpoint Therapeutics' score of -0.20 indicating that Checkpoint Therapeutics is being referred to more favorably in the media.
Checkpoint Therapeutics presently has a consensus target price of $22.60, suggesting a potential upside of 1,286.50%. AEON Biopharma has a consensus target price of $6.00, suggesting a potential upside of 279.75%. Given AEON Biopharma's higher probable upside, research analysts plainly believe Checkpoint Therapeutics is more favorable than AEON Biopharma.
AEON Biopharma has a net margin of 0.00% compared to AEON Biopharma's net margin of -50,336.89%.
AEON Biopharma has lower revenue, but higher earnings than Checkpoint Therapeutics.
Summary
Checkpoint Therapeutics beats AEON Biopharma on 7 of the 13 factors compared between the two stocks.
Get AEON Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for AEON and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AEON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AEON Biopharma Competitors List
Related Companies and Tools
